Andrew Makrides - 10 Aug 2023 Form 4 Insider Report for Apyx Medical Corp (APYX)

Reporting relationship: Director
Issuer ticker: APYX
Reported as of: 10 Aug 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Aug 2023, 12:27:35 UTC
Prior SEC filing: 17 Aug 2022
Source filing: View source filing
Reporting owner signature: /s/ Andrew Makrides

Key filing fact

Andrew Makrides filed Form 4 for Apyx Medical Corp (APYX) on 15 Aug 2023.

Key facts

This page summarizes Andrew Makrides's Form 4 filing for Apyx Medical Corp (APYX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Aug 2023, 12:27.

Change

Previous filing in this sequence was filed on 17 Aug 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APYX transaction Derivative

Stock Option (Option to Buy)

Award

Transaction value: $0
Shares: -17,000
Change %: -50%
Price: $0.000000
Shares after: 17,000
Date: 10 Aug 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,000
Exercise price: $4.25
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Reporting person was granted a stock option which shall vest ratably over a twelve (12) month period and shall become fully vested and fully exercisable on the first anniversary of the date of grant.